# Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

> **NCT07002320** · PHASE1,PHASE2 · RECRUITING · sponsor: **Institute of Cancer Research, United Kingdom** · enrollment: 78 (estimated)

## Conditions studied

- Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** SX-682
- **DRUG:** Apalutamide

## Key facts

- **NCT ID:** NCT07002320
- **Lead sponsor:** Institute of Cancer Research, United Kingdom
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-28
- **Primary completion:** 2029-10
- **Final completion:** 2029-10
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07002320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07002320, "Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07002320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*